Atara Biotherapeutics, Inc. (ATRA)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Atara Biotherapeutics, Inc. (ATRA)
Go deeper and ask any question about ATRA
Company Performance
Current Price
as of Sep 13, 2024$9.72
P/E Ratio
N/A
Market Cap
$55.15M
Description
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
Metrics
Overview
- HQThousand Oaks, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerATRA
- Price$9.72+20.30%
Trading Information
- Market Cap$55.15M
- Float64.88%
- Average Daily Volume (1m)217,711
- Average Daily Volume (3m)249,604
- EPS-$39.12
Company
- Revenue$62.39M
- Rev Growth (1yr)2,892.69%
- Net Income-$19.05M
- Gross Margin83.84%
- EBITDA Margin-57.77%
- EBITDA-$16.54M
- EV$106.61M
- EV/Revenue1.71
- P/EN/A
- P/S0.96
Documents
SEC Filings
Factset Street Account